According to information provided in a press release, Alentis was founded upon the research work conducted by the laboratory of Professor Thomas Baumert of the University of Strasbourg. Additional scientific institutions were also involved in founding Alentis, such as SATT Conectus, an organization for accelerating technology transfer based in Alsace, France, and Professor Yujin Hoshida of the University of Texas Southwestern in Dallas. Moreover, BaseLaunch, a healthcare accelerator operated by BaselArea.swiss, was instrumental in offering key support to Alentis immediately following the company’s founding. As a result of this, Alentis’s headquarters are now also located in Basel, with a subsidiary in Strasbourg and additional branch in Germany.
Alentis boasts a proprietary platform on the basis of which drugs to treat liver diseases and cancer can be developed. Its most highly developed product candidate is a humanized monoclonal antibody, which has been developed to treat both liver fibrosis in addition to hepatocellular carcinoma (HCC).
For this reason, Alentis has now been able to successfully appeal to a whole host of investors. The company has raised 12.5 million francs as part of a Series A financing round. The Basel-based BioMedPartners and BB Pureos Bioventures co-led the financing round, while BPI France, Schroder Adveq and the German High-Tech Gründerfonds (HTGF) were also all involved in the process. Andreas Wallnöfer, General Partner at BioMedPartners, is set to become a member of the Supervisory Board at Alentis. He described Baumert’s research as “truly translational” in the press release, with the result that a rapid transition from preclinical research to clinical development can be expected.